David Paul Sanden

Title: David Paul Sanden: Innovator in Aurora Kinase Research

Introduction

David Paul Sanden is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of biochemistry, particularly in the study of Aurora kinases. With a total of 2 patents, Sanden's work focuses on methods that enhance our understanding of these critical enzymes.

Latest Patents

Sanden's latest patents include a method for crystallizing the Aurora 2 kinase catalytic domain polypeptide. This invention discloses nucleic acids that encode an active human Aurora 2 kinase catalytic domain. It also outlines methods for growing X-ray diffractable crystals of polypeptides that comprise this active domain. Furthermore, the invention presents a crystalline form of the catalytic domain of human Aurora 2 kinase. It details methods for using these X-ray diffractable crystals in structure-assisted drug design to identify compounds that can modulate the enzymatic activity of human Aurora 2 kinase. Another patent focuses on the crystalline form of the catalytic domain of Aurora 2 kinase and methods of use thereof, reiterating the importance of these advancements in drug design.

Career Highlights

David Paul Sanden is currently associated with Schering Corporation, where he continues to innovate in the field of biochemistry. His work has been instrumental in advancing the understanding of Aurora kinases, which play a vital role in cell division and cancer research.

Collaborations

Sanden has collaborated with notable colleagues such as Thierry Olivier Fischmann and Vincent Stewart Madison. Their combined expertise has contributed to the successful development of innovative solutions in their field.

Conclusion

David Paul Sanden's contributions to the field of Aurora kinase research are significant and impactful. His patents reflect a commitment to advancing scientific knowledge and improving drug design methodologies.